CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma
1998; Wiley; Volume: 34; Issue: 1 Linguagem: Inglês
10.1002/(sici)1097-0320(19980215)34
ISSN1097-0320
AutoresPhillip Ruiz, Sylvain Mailhot, Patricia Delgado, Alexandra Amador, Ana L. Viciana, Lluís Ferrer, Natalia Zacharievich,
Tópico(s)Glycosylation and Glycoproteins Research
ResumoCytometryVolume 34, Issue 1 p. 30-35 Case ReportFree Access CD26 expression and dipeptidyl peptidase IV activity in an aggressive hepatosplenic T-cell lymphoma Phillip Ruiz, Corresponding Author Phillip Ruiz pruiz@mednet.med.miami.edu Department of Pathology, University of Miami School of Medicine, Miami, Florida Department of Microbiology/Immunology, University of Miami School of Medicine, Miami, Florida Department of Surgery, University of Miami School of Medicine, Miami, FloridaDepartment of Pathology (D-33), University of Miami School of Medicine, P.O. Box 016960, Miami, FL 33101Search for more papers by this authorSylvain Mailhot, Sylvain Mailhot Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this authorPatricia Delgado, Patricia Delgado Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this authorAlexandra Amador, Alexandra Amador Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this authorAna L. Viciana, Ana L. Viciana Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this authorLuis Ferrer, Luis Ferrer Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this authorNatalia Zacharievich, Natalia Zacharievich Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this author Phillip Ruiz, Corresponding Author Phillip Ruiz pruiz@mednet.med.miami.edu Department of Pathology, University of Miami School of Medicine, Miami, Florida Department of Microbiology/Immunology, University of Miami School of Medicine, Miami, Florida Department of Surgery, University of Miami School of Medicine, Miami, FloridaDepartment of Pathology (D-33), University of Miami School of Medicine, P.O. Box 016960, Miami, FL 33101Search for more papers by this authorSylvain Mailhot, Sylvain Mailhot Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this authorPatricia Delgado, Patricia Delgado Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this authorAlexandra Amador, Alexandra Amador Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this authorAna L. Viciana, Ana L. Viciana Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this authorLuis Ferrer, Luis Ferrer Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this authorNatalia Zacharievich, Natalia Zacharievich Department of Pathology, University of Miami School of Medicine, Miami, FloridaSearch for more papers by this author First published: 26 December 2002 https://doi.org/10.1002/(SICI)1097-0320(19980215)34:1 3.0.CO;2-ICitations: 21AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract The transmembrane serine aminopeptidase dipeptidyl peptidase IV (DPP IV) (also known as CD26) participates in several immunological functions and has a binding affinity for several molecules, including collagen, which may be an integral mechanism for T cells to traverse endothelial barriers. Since CD26 is phenotypically expressed in certain T-cell malignancies, this study utilized a novel four-color cytofluorographic procedure to measure DPP IV enzymatic activity concurrently with the expression of other surface markers in an aggressive hepatosplenic T-cell lymphoma. Immunophenotypic analysis by flow cytometry revealed the tumor to be CD2+, CD3+, CD5−, CD7+, TcR−γ/δ+, CD4−, CD8±, CD56+, and CD11c+. The CD26 molecule was also expressed, and DPP IV activity was present, with the maximal activity detectable after 10 min of incubation. These results represent the initial description of enzymatically active CD26 in a T-cell malignancy, and raise the possibility that this molecule may be a participant in the pathogenetic mechanisms utilized by the neoplastic cells. Cytometry (Comm. Clin. Cytometry) 34:30–35, 1998. © 1998 Wiley-Liss, Inc. Literature Cited 1 Ulmer A, Mattern T, Feller A, Heymann E, Flad HD: CD26 antigen is a surface dipeptidyl peptidase IV (DPP IV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7. Scand J Immunol 31: 429– 435, 1990. 2 Shipp MA, Look AL: Hematopoietic differentiation antigens that are membrane associated enzymes: Cutting is the key Blood 82: 1052– 1070, 1993. 3 De Meester I, Vanhoof G, Hendriks D, Demuth HU, Yaron A, Scarpe S: Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes. Clin Chim Acta 210: 23– 34, 1992. 4 Abbott CA, Baker E, Sutherland GR, McCaughan GW: Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 40: 331– 338, 1994. 5 Droz D, Zachar D, Charbit L, Gogusev Chretien JY, Iris L: Expression of human nephron differentiation molecules in renal cell carcinoma. Am J Pathol 137: 895– 905, 1990. 6 Walter R, Simmons WH, Yoshimoto T: Proline specific endo- and exopeptidases. Mol Cell Biochem 30: 111– 127, 1980. 7 Mattern T, Reich C, Duchrow M, Ansorge S, Ulmer AJ, Flad HD: Antibody-induced modulation of CD26 surface expression. Immunology 84: 595– 600, 1995. 8 Shimizu Y, Shaw S: Lymphocyte interactions with extracellular matrix. FASEB J 5: 2292– 2299, 1991. 9 Naquet P, Vivier I, Gorvel JP, Brekelmans P, Barad M, Bernard AM, Pierres M: Activation of mouse T lymphocytes by a monoclonal antibody to a developmentally regulated surface aminopeptidase. Immunol Rev 111: 177– 193, 1989. 10 Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C: Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol 147: 2514– 2517, 1991. 11 Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C: Direct association of adenosine deaminase with a T cell activation antigen CD26. Science 261: 466– 469, 1993. 12 Schon E, Jahn S, Kiessig HU, Demuth K, Neubert A, Barth R, Baehr V, Ansorge S: The role of dipeptidyl peptidase IV in human T lymphocyte activation inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol 17: 1821– 1826, 1987. 13 Buhling F, Junker U, Reinhold D, Neubert K, Jager L, Ansorge S: Functional role of CD26 on human B lymphocytes. Immunol Lett 45: 47– 51, 1995. 14 Buhling F, Dunz D, Reinhold D, Ulmer AJ, Ernst M, Flad HD, Ansorge S: Expression and functional role of dipeptidyl peptidase IV on human natural killer cells. Nat Immun 13: 270– 279, 1994. 15 Martin M, Huguet J, Centelles JJ, Franco R: Expression of ectoadenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. J Immunol 155: 4630– 4643, 1995. 16 Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C: Comitogenic effect of solid phase immunobilized anti-IF7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 144: 4092– 4100, 1990. 17 Bednarczyk J, Carroll SM, Marin C, McIntyre B: Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation. J Cell Biochem 46: 206– 218, 1991. 18 Ruiz P, Nassiri M, Steele B, Viciana AL: Cytofluorographic evidence that thymocyte dipeptidyl peptidase IV (CD26) activity is altered with stage of ontogeny and apoptotic status. Cytometry 23: 322– 329, 1996. 19 Bauvois B: Murine thymocytes possess specific cell surface-associated exoaminopeptidase activities: Preferential expression by immature CD4-CD8-subpopulation. Eur J Immunol 20: 459– 468, 1990. 20 Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C: The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 90: 4586– 4590, 1993. 21 Carbone A, Gloghini A, Zagonel V, Aldinucci D, Gattei V, Degan M, Improta S, Sorio R, Monfardini S, Pinto A: The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood 86: 4617– 4626, 1995. 22 Kondo S, Kotani T, Tamura K, Aratke Y, Uno H, Tsubouchi H, Inoue S, Niho Y, Ohtaki S: Expression of CD26/dipeptidyl peptidase IV in adult T cell leukemia/lymphoma (ATLL). Leuk Res 20: 357– 363, 1996. 23 Carbone A, Gloghini A, Zagonel V, Pinto A: An update on the diagnostic relevance of CD26 antigen expression in CD30 positive anaplastic large cell lymphomas. Hum Pathol 26: 1169– 1170, 1995. 24 Garcia-Sanchez F, Menarguez J, Cristobal E, Cantalejo A, Gil J, Algara P, Vicario JL: Hepatosplenic gamma-delta T-cell malignant lymphoma: Report of the first case in childhood, including molecular minimal residual disease follow-up. Br J Haematol 90: 943– 946, 1995. 25 Cooke CB, Krenacs L, Stetler-Stevenson M, Greiner TC, Raffeld M, Kingma DW, Abruzzo L, Frantz C, Kaviani M, Jaffe ES.: Hepatosplenic T-cell lymphoma: A distinct clinicopathologic entity of cytotoxic gamma-delta T-cell origin. Blood 88: 4265– 4274, 1996. 26 Emil JF, Boulland ML, Haioun C, Kanavaros P, Petrella T, Delfau-Larue MH, Bensussan A, Farcet JP, Gaulard P: CD52 CD561 T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 87: 1466– 1473, 1996. 27 Assfalg-Machleidt I, Rothe G, Klingel S, Banati R, Mangel WF, Valt G, Machleidt W: Membrane permeable fluorogenic rhodamine substrates for selective determination of cathepsin L. Biol Chem Hoppe Seyler 373: 433– 440, 1992. 28 Leytus SP, Patterson WL, Mangel WF: New class of sensitive and selective fluorogenic substrates for serine proteinases. Biochem J 215: 253– 260, 1983. 29 Krishan A: Flow cytometric studies on intracellular drug resistance. In: Techniques in Cell Cycle Analysis, JW Gray, Z Darzynkiewicz (eds): Clifton, NJ: Humana Press, 1997, pp 337– 366. 30 Alhanaty E, Shaltiel S: Limited proteolysis of the catalytic subunit of cAMP-dependent protein kinase: A membranal regulatory device 656. Biochem Biophys Res Commun 89: 323– 332, 1979. 31 Mundy DI, Strittmatter WJ: Requirement for metalloendoprotease in exocytosis. Evidence in mast cells and adrenal chromaffin cells. Cell 40: 645– 656, 1985. 32 Di Stefano JF, Beck G, Lane B, Zucker S: Role of tumor cell membrane-bound serine proteases in tumor-induced target cytolysis. Cancer Res 42: 207– 218, 1982. 33 Scholz W, Mentlein R, Heymann E, Feller AC, Ulmer AJ, Flad HD: Interleukin 2 production by human T lymphocytes identified by antibodies to dipeptidyl peptidase IV. Cell Immunol 93: 199– 211, 1985. 34 Morimoto C, Schlossman SF: CD 26: A key costimulatory molecule on CD4 memory T cells. Immunologist 2: 4– 7, 1994. 35 Ruiz P, Hao L, Zucker K, Zacharievich N, Viciana AV, Shenkin M, Miller J: Dipeptidyl peptidase IV (CD26) activity in human alloreactive T cell subsets varies with the stage of differentiation and activation status. Transplant Immunol 5: 152– 161, 1997. Citing Literature Volume34, Issue115 February 1998Pages 30-35 ReferencesRelatedInformation
Referência(s)